Transaction DateRecipientSharesTypePriceValue
4th January 2021Joseph W Iii Marshall3,656Grant/award etc.$0.00
4th January 2021Joseph W Iii Marshall4,128Grant/award etc.$0.00
27th August 2020James Antal30,000Open or private sale$7.10$213,000.00
12th August 2020Eric A Md Rose661Grant/award etc.$0.00
7th August 2020Eric A Md Rose422Payment by withholding$314.98$132,921.56
31st July 2020Robin Elizabeth Abrams14,138Payment by withholding$6.42$90,765.96
31st July 2020Robin Elizabeth Abrams26,667Exercise of derivative$0.00
31st July 2020Daniel J Luckshire13,005Payment by withholding$6.42$83,492.10
31st July 2020Daniel J Luckshire26,667Exercise of derivative$0.00
21st May 2020Jeffrey B Kindler15,000Exercise of derivative$0.00
Siga Technologies
Siga Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.

Ticker: SIGA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1010086
Employees: 41
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $53 M (0%)
Inventory, Net: $14 M (0%)
Assets, Current: $105 M (-41%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $902 Th (5%)
Assets: $120 M (-39%)
Accounts Payable, Current: $630 Th (-79%)
Accrued Liabilities, Current: $15 M (0%)
Liabilities, Current: $16 M (-83%)
Liabilities: $26 M (-73%)
Common Stock, Value, Issued: $8 Th (-3%)
Common Stock, Shares, Issued: $79 M (-3%)
Additional Paid in Capital, Common Stock: $221 M (0%)
Retained Earnings (Accumulated Deficit): $127 M (3%)
Stockholders' Equity (Parent): $94 M (0%)
Liabilities and Equity: $120 M (-39%)
Revenue: $40 M (-6%)
Cost of Revenue: $5 M (-2%)
Research and Development: $3 M (-53%)
Operating Income/Loss: $29 M (16%)
Other Income, net: $32 Th (-92%)
Income before taxes: $27 M (74%)
Provision for income taxes: $6 M (0%)
EPS (basic): $0.26 (0%)
EPS (diluted): $0.26 (0%)